Improving the diffraction quality of heat-shock protein 47 crystals
Kevin Kish1, Stephen Cobell1, Nicolas Szapiel2
1Molecular Structure & Design, Bristol Myers Squibb Research & Development, PO Box 4000, Princeton, NJ 08543-4000, USA.
Acta Crystallographica. Section F, Structural Biology Communications
|October 14, 2024
Summary
Researchers aimed to develop a drug-design system targeting heat-shock protein 47 (HSP47) to combat fibrosis. They overcame crystallization challenges using modified His-tags and Adnectin chaperones, enabling better structural analysis of HSP47.
Area of Science:
- Biochemistry
- Structural Biology
- Drug Discovery
Background:
- Heat-shock protein 47 (HSP47) is crucial for collagen folding and assembly, making it a therapeutic target for fibrotic diseases.
- Previous attempts to crystallize apo dog HSP47 for structure-based drug design were hampered by difficulties in obtaining high-quality crystals and resolving the structure.
Purpose of the Study:
- To develop a robust structure-based drug-design system for HSP47 inhibitors.
- To overcome crystallization challenges previously encountered with apo dog HSP47.
Main Methods:
- Investigated strategies to improve crystal formation and diffraction of HSP47.
- Modified the His-tag location and cleavability (N-terminus).
- Developed and utilized Adnectin crystallization chaperones.
Main Results:
- Initial attempts with C-terminal His-tag resulted in poorly diffracting tetrameric structures with multiple HSP47 molecules per asymmetric unit.
- Moving the His-tag to the N-terminus and making it cleavable improved crystal quality.
- Adnectin chaperones yielded well-diffracting crystals with fewer HSP47 molecules per asymmetric unit, simplifying model building.
Conclusions:
- Successful crystallization of HSP47 was achieved through strategic modifications of purification tags and the use of crystallization chaperones.
- These improved methods facilitate detailed structural analysis of HSP47, paving the way for structure-based inhibitor design.
- The developed crystallization strategies are valuable for advancing therapeutic strategies against fibrotic conditions targeting HSP47.


